Toll-like receptor-9 in Spanish multiple sclerosis patients: An association with the gender

European Journal of Neurology

Volumn 21, Issue 3, 2014, Pages 537-540

  Dominguez Mozo, M I ^a   Garcia Montojo, M ^a   Lopez Cavanillas M ^a   De Las Heras, V ^a   Garcia Martinez, A ^a   Arias Leal, A M ^a   Casanova, I ^a   Urcelay, E ^a   Arroyo, R ^a   Alvarez Lafuente, R ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Gender; Multiple sclerosis; TLR9

Indexed keywords

GENDER; MULTIPLE SCLEROSIS; TLR9;

COHORT STUDIES; DISABILITY EVALUATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS; SPAIN; STATISTICS, NONPARAMETRIC; TOLL-LIKE RECEPTOR 9;

EID: 84893854637     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12209     Document Type: Article

References (13)

1. Cook S, Rohowsky-Kochan C, Bansil S, Dowling P. Evidence for a viral etiology of multiple sclerosis. 2. In: Cook S, ed. Handbook of Multiple Sclerosis. New York: Marcel Dekker, Inc., 1996: 97-118.
2. Ronkainen H, Hirvikoski P, Kauppila S, et al. Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. J Exp Clin Cancer Res 2011; 30: 84-89.
3. Guggemoos S, Hangel D, Hamm S, et al. TLR9 contributes to antiviral immunity during gammaherpesvirus infection. J Immunol 2008; 180: 438-443.
4. Segal BM, Chang JT, Shevach EM. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J Immunol 2000; 164: 5683-5688.
5. Prinz M, Garbe F, Schmidt H, et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 2006; 116: 456-464.
6. Chen KH, Zeng L, Gu W, et al. Polymorphisms in the toll-like receptor 9 gene associated with sepsis and multiple organ dysfunction after major blunt trauma. Br J Surg 2011; 98: 1252-1259.
7. Tomassini V, Pozzilli C. Sex hormones: a role in the control of multiple sclerosis? Expert Opin Pharmacother 2006; 7: 857-868.
8. Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999; 67: 148-152.
9. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116: 117-134.
10. Wolfson C, Confavreux C. A Markov model of the natural history of multiple sclerosis. Neuroepidemiology 1985; 4: 227-239.
11. Weinshenker BG, Rice GP, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991; 114: 1045-1056.
12. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: anamnesic process. Brain 2003; 126: 770-782.
13. De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41: 776-782.